38 results on '"Hurteau, Jean A."'
Search Results
2. Starting dose of niraparib as first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real- world database (352)
3. Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers
4. Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?
5. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
6. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
7. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations
8. Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study
9. Patterns and utility of routine surveillance in high grade endometrial cancer
10. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
11. The 2012 Annual Meeting on Women's Cancer
12. Nonsteroidal antiinflammatory drugs and progestins synergistically enhance cell death in ovarian epithelial cells
13. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies
14. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
15. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer
16. Effects of omega-3 fatty acids on components of the transforming growth factor beta-1 pathway: implication for dietary modification and prevention in ovarian cancer
17. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy
18. The effects of Omega-3 fatty acids on growth regulation of epithelial ovarian cancer cell lines
19. Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients
20. Visualization of the epigastric vessels and bladder before laparoscopic trocar placement
21. Overexpression of a Stabilized Mutant Form of the Cyclin-Dependent Kinase Inhibitor p27Kip1 Inhibits Cell Growth
22. Effect of carbon dioxide on human ovarian carcinoma cell growth
23. Expression and Subcellular Localization of the Cyclin-Dependent Kinase Inhibitor p27Kip1 in Epithelial Ovarian Cancer
24. Reply
25. Cervical Primitive Neuroectodermal Tumor
26. Evaluation of Recombinant Human Interleukin-12 in Patients with Recurrent or Refractory Ovarian Cancer: A Gynecologic Oncology Group Study
27. Regulation of Invasion of Epithelial Ovarian Cancer by Transforming Growth Factor-β
28. Location of the ureters in relation to the uterine cervix by computed tomography
29. FIGO Stage IIIC Endometrial Carcinoma with Metastases Confined to Pelvic Lymph Nodes: Analysis of Treatment Outcomes, Prognostic Variables, and Failure Patterns Following Adjuvant Radiation Therapy
30. Trisomy 21 Associated with Ovarian Dysgerminoma
31. Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study
32. Location of the transverse colon in relationship to the umbilicus: Implications for laparoscopic techniques
33. Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent
34. Reply
35. Evaluation of Cisplatin and Cyclosporin A in Recurrent Platinum-Resistant Ovarian Cancer: A Phase II Study of the Gynecologic Oncology Group
36. A Prospective Controlled Trial of Early Postoperative Oral Intake Following Major Abdominal Gynecologic Surgery
37. Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas
38. Levels of soluble interleukin-2 receptor-α are elevated in serum and ascitic fluid from epithelial ovarian cancer patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.